Charles Schwab’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Charles Schwab’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-30,308	Closed	-$81K	–	3419
2020 Q1	$81K	Hold	30,308	–	–	﹤0.01%	3126
2019 Q4	$36K	Hold	30,308	–	–	﹤0.01%	3142
2019 Q3	$53K	Hold	30,308	–	–	﹤0.01%	3120
2019 Q2	$144K	Hold	30,308	–	–	﹤0.01%	3112
2019 Q1	$196K	Buy	30,308 +18,328	+153%	+$96K	﹤0.01%	3027
2018 Q4	$61K	Hold	11,980	–	–	﹤0.01%	3122
2018 Q3	$103K	Buy	+11,980	New	+$133K	﹤0.01%	3114

Charles Schwab's NTGN Position: Q2 2020 in Review

Charles Schwab sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 30,308 shares — an estimated $81K sold.

Charles Schwab first reported a position in NTGN in Q3 2018 and held it in 7 quarters. The position peaked at $196K in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Charles Schwab reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Charles Schwab sold 30,308 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $81K.
Charles Schwab first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
Charles Schwab's Neon Therapeutics, Inc. Common Stock position peaked at $196K in Q1 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Charles Schwab's 13F filing for Q2 2020, filed 14 Aug 2020.